SEC ownership of DR REDDYS LABORATORIES LTD

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001135951.

Comparable stake leader

G. Prasad V

Disclosed value leader

G. Prasad V

Comparable rows

50/50

Latest evidence

31 Mar 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 2 signals
Latest 13D/G holder
G. Prasad V
Latest parsed ownership date
31 Mar 2026
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001135951
Issuer location
Hyderabad

Ownership snapshot

Top shareholders of DR REDDYS LABORATORIES LTD (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
G. Prasad V
Disclosed value leader
G. Prasad V
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G 3/4/5 13F Lead comparable stake: 14% 13D/G row: G. Prasad V Showing 1-8 of 50 holder rows.

Quick read

G. Prasad V leads the comparable SEC ownership view at 14%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens G. Prasad V's linked filing trail.
Comparable ownership Top 5
G. Prasad V 14%
BlackRock, Inc. 4.1%
Robeco Institutional Asset Manage... 2.1%
ROYAL BANK OF CANADA 1.2%
MORGAN STANLEY 1.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
G. Prasad V
13D/G 3/4/5
K. Satish Reddy · Director
14%
$1,607,395,312
113,356,510 shares
$0 17 Sep 2025
BlackRock, Inc.
13F 13D/G
Company
4.1%
from 13D/G
$160,481,704
11,587,127 shares
31 Mar 2026
Robeco Institutional Asset Management B.V.
13F
Company
13F
2.1%
$237,913,669
17,177,882 shares
31 Mar 2026
ROYAL BANK OF CANADA
13F
Company
13F
1.2%
$138,293,000
9,984,081 shares
31 Mar 2026
MORGAN STANLEY
13F
Company
13F
1.1%
$129,796,619
9,371,594 shares
31 Mar 2026
Aikya Investment Management Ltd
13F
Company
13F
0.96%
$110,797,175
7,999,796 shares
31 Mar 2026
RENAISSANCE TECHNOLOGIES LLC
13F
Company
13F
0.94%
$108,857,233
7,859,728 shares
31 Mar 2026
DIMENSIONAL FUND ADVISORS LP
13F
Company
13F
0.64%
$73,667,799
5,323,248 shares
31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 08 Jun 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-19 of 19 reporting-owner rows connected to DR REDDYS LABORATORIES LTD. Open a relationship link for the CIK-to-CIK filing trail.

Rows
19
Largest Forms 3/4/5 holder
G. Prasad V
Net 12M change
$0
Latest report
01 Apr 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
G. Prasad V Director Mixed 18 Dec 2025
Satish Reddy K. Director Mixed 18 Dec 2025
Shikha Sanjaya Sharma Director Mixed 18 Dec 2025
Arun Madhavan Kumar Director Mixed 18 Dec 2025
Leo Puri Director Mixed 18 Dec 2025
Krishnan Kodumudi Pranatharthiharan Director Mixed 18 Dec 2025
Penny Chan Wan Director Mixed 18 Dec 2025
Sanjiv Soshil Mehta Director Mixed 18 Dec 2025
Alpna Seth Director Mixed 18 Dec 2025
Deepak Sapra CEO - API and Services Mixed 18 Dec 2025
Venkata Narasimham Mannam Chief Financial Officer Mixed 18 Dec 2025
Srinivasa Phanimitra Bhethanabottla Chief Information Officer Mixed 18 Dec 2025
Sushrut Kulkarni Global Head Ipdo Mixed 18 Dec 2025
Krishna Venkatesh Global Head - IPDO Mixed 18 Dec 2025
Erez Israeli Chief Executive Officer Mixed 18 Dec 2025
Venkata Ramana Motupalli CEO - Global Generics Mixed 18 Dec 2025
Milan Kantilal Kalawadia CEO - North America Mixed 18 Dec 2025
Patrick Rudolf Aghanian Head - Europe Generics Mixed 18 Dec 2025
Madhu Sundar Subramanian Munnirpallam Global Head of Quality and PV Mixed 01 Apr 2026

Recent insider transactions for DR REDDYS LABORATORIES LTD

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Madhu Sundar Subramanian Munnirpallam RDY Equity Shares 0 35,600 01 Apr 2026 Direct
Patrick Rudolf Aghanian RDY Equity Shares underlying ADRs 0 8,450 18 Dec 2025 Direct
Milan Kantilal Kalawadia RDY Equity Shares underlying ADRs 0 47,325 18 Dec 2025 Direct
Venkata Ramana Motupalli RDY Equity Shares 0 68,230 18 Dec 2025 Direct
Sushrut Kulkarni RDY Equity Shares 0 70 18 Dec 2025 Direct
Srinivasa Phanimitra Bhethanabottla RDY Equity Shares 0 8,712 18 Dec 2025 Direct
Venkata Narasimham Mannam RDY Equity Shares 0 61,245 18 Dec 2025 Direct
Deepak Sapra RDY Equity shares 0 75,624 18 Dec 2025 Direct
Satish Reddy K. RDY Equity shares 0 75,630,620 18 Dec 2025 By VSD Family Trust (as a Trustee)
Satish Reddy K. RDY Equity shares 0 27,618,385 18 Dec 2025 By Kallam Satish Reddy HUF
Satish Reddy K. RDY Equity Shares 0 10,107,505 18 Dec 2025 Direct
G. Prasad V RDY Equity shares 0 96,095,920 18 Dec 2025 By GVP Family Trust ( as a Trustee)
G. Prasad V RDY Equity shares 0 12,717,090 18 Dec 2025 By Gunupati Venkateswara Prasad HUF
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .